
| RESEARCH ARTICLE**Investigation of Advances in Breast Cancer Screening Technologies****Elvis Ngolle Ngolle**

Faculty of medicine University of Buea Cameroon

Corresponding Author: Elvis Ngolle Ngolle, **E-mail:** elvisngolle89@gmail.com

| ABSTRACT

Breast cancer remains one of the leading causes of morbidity and mortality among women worldwide, making early detection a critical component in improving survival outcomes. Advances in screening technologies over the past two decades have significantly enhanced the accuracy, accessibility, and effectiveness of breast cancer diagnostics. This review article investigates recent innovations in breast cancer screening, focusing on the progression from traditional imaging modalities to emerging, technology-driven approaches. Conventional methods such as mammography, ultrasound, and magnetic resonance imaging (MRI) continue to form the foundation of screening programs; however, each presents limitations related to sensitivity, specificity, radiation exposure, or cost. In response, novel technologies have emerged to address these gaps and provide more reliable diagnostic pathways. The study highlights major technological developments including digital breast tomosynthesis (3D mammography), contrast-enhanced mammography, automated breast ultrasound (ABUS), and advanced MRI techniques that offer improved lesion detection, particularly in women with dense breast tissue. Additionally, the integration of Artificial Intelligence (AI) and machine learning into imaging interpretation has transformed diagnostic workflows by reducing human error, enhancing image analysis precision, and supporting risk-stratified screening approaches. Molecular imaging modalities, such as positron emission mammography (PEM) and optical imaging, further demonstrate growing potential for early detection at the cellular and metabolic levels. Emerging non-invasive and minimally invasive innovations, including liquid biopsies and circulating biomarkers, are also explored as promising complementary tools for personalized screening strategies. While these advancements demonstrate strong potential, challenges remain in terms of cost, accessibility in low-resource settings, standardization, and long-term clinical validation. Overall, this investigation underscores that continuous technological evolution in breast cancer screening is driving earlier diagnosis, more accurate risk assessment, and better patient outcomes. However, equitable implementation, multidisciplinary collaboration, and sustained research are essential to fully realize the benefits of these innovations in global healthcare systems.

| KEYWORDS

Breast cancer, screening, mammography, artificial intelligence, early detection, imaging technologies

| ARTICLE INFORMATION**ACCEPTED:** 09 October 2025**PUBLISHED:** 11 December 2025

1. Introduction

Breast cancer remains a significant global health challenge and is among the leading causes of cancer-related mortality in women (Wright & McGeachan, 2003; Greenwood, Dodelzon, & Katzen, 2018). According to recent international health reports, its incidence continues to rise due to a combination of genetic, environmental, lifestyle, and reproductive factors (Abdul Halim et al., 2021). Despite this growing prevalence, early detection has consistently been shown to improve treatment outcomes, reduce mortality rates, and enhance the quality of life for affected individuals (Irwig, Houssami, & Van Vliet, 2004). Consequently, breast cancer screening has become a critical component of public health strategies worldwide. As medical technology advances, the

landscape of screening is experiencing rapid transformation, offering new opportunities to detect malignancies earlier and more accurately than ever before (Alshawwa et al., 2024; Lafi et al., 2024).

Traditional breast cancer screening techniques—such as mammography, ultrasound, and magnetic resonance imaging (MRI)—have long served as the primary diagnostic tools (Smith & Andreopoulou, 2004; Gegios, Peterson, & Fowler, 2023). Mammography, in particular, has been instrumental in reducing breast cancer deaths through early detection. However, conventional methods are not without limitations. Challenges such as reduced sensitivity in women with dense breast tissue, false positives and negatives, radiation exposure, interpretive variability, and cost constraints continue to affect their overall effectiveness (Irwig, Houssami, & Van Vliet, 2004; Greenwood, Dodelzon, & Katzen, 2018). These limitations have driven researchers and clinicians to explore more sophisticated screening technologies that can overcome existing gaps and better support early, precise diagnosis (Ayer, 2015).

In recent years, unprecedented technological progress has propelled the development of advanced screening modalities. Digital breast tomosynthesis (3D mammography), contrast-enhanced mammography, automated breast ultrasound (ABUS), and improved MRI techniques have demonstrated enhanced accuracy and diagnostic confidence (Smith, Hall, & Marcello, 2004; Vaughan, 2019). Parallel to these advancements, artificial intelligence (AI) and machine learning have begun to revolutionize imaging interpretation. AI-powered systems can analyze complex imaging patterns, assist clinicians in detecting subtle abnormalities, reduce diagnostic errors, and facilitate individualized screening strategies based on patient risk profiles (Díaz, Rodríguez-Ruíz, & Sechopoulos, 2024).

Beyond imaging innovations, emerging research in molecular diagnostics and non-invasive biomarker detection is expanding the scope of early detection. Techniques such as liquid biopsies, which analyze circulating tumor cells and DNA fragments, offer the potential to identify cancer signatures before they become visible on imaging scans (Pulumati et al., 2023). Similarly, molecular imaging approaches—such as positron emission mammography (PEM) and optical breast imaging—enable the visualization of metabolic and functional changes that precede structural alterations in breast tissue (Mincey & Perez, 2004).

Despite these promising advancements, challenges persist relating to cost, infrastructure requirements, availability in low-resource settings, patient awareness, and the need for thorough clinical validation (Alshawwa et al., 2024; Lafi et al., 2024). Ensuring equitable access to advanced screening technologies remains a major concern. Additionally, integrating new technologies into existing healthcare systems requires multidisciplinary collaboration, updated clinical guidelines, and ongoing training for practitioners (Greenwood, Dodelzon, & Katzen, 2018).

This article investigates the latest advances in breast cancer screening technologies, evaluating their potential to enhance early detection, improve diagnostic accuracy, and support personalized care (Abdul Halim et al., 2021; Vaughan, 2019). By examining recent innovations and the challenges associated with their implementation, this study contributes to a broader understanding of how evolving technologies can shape the future of breast cancer screening and ultimately improve patient outcomes.

2. Literature Review

2.1 Overview of Breast Cancer Screening and Historical Perspective

Breast cancer screening has undergone significant evolution over the past five decades, shifting from basic palpation-based clinical exams to highly sophisticated imaging technologies (Wright & McGeachan, 2003; Irwig, Houssami, & Van Vliet, 2004). Historically, conventional mammography emerged as the primary screening tool due to its ability to detect microcalcifications indicative of early malignancies. Despite its effectiveness, traditional mammography has been criticized for reduced sensitivity among women with dense breast tissue and for generating false positives that may lead to unnecessary biopsies (Smith & Andreopoulou, 2004). These early limitations laid the foundation for continued research into more advanced diagnostic methods capable of improving accuracy and early detection (Abdul Halim et al., 2021).

2.2 Advances in Digital and Enhanced Mammography

Digital mammography has largely replaced film-based systems, offering better image clarity, improved storage, and the ability to manipulate images for enhanced visualization (Gegios, Peterson, & Fowler, 2023). Digital Breast Tomosynthesis (DBT), or 3D mammography, captures multiple images from different angles, which enhances lesion detection and reduces recall rates (Smith, Hall, & Marcello, 2004). Studies demonstrate that DBT significantly improves cancer detection rates, particularly for invasive tumors, making it a preferred technique in many clinical settings (Vaughan, 2019).

2.3 Innovations in Ultrasound-Based Screening Technologies

Ultrasound has traditionally been used as a supplementary tool to mammography, particularly for women with dense breast tissue (Irwig, Houssami, & Van Vliet, 2004). Automated Breast Ultrasound (ABUS) increases reproducibility, reduces operator dependency, and provides comprehensive imaging of the entire breast (Alshawwa et al., 2024). Advanced ultrasound techniques such as elastography improve tissue characterization and diagnostic confidence (Lafi et al., 2024).

2.4 Progress in MRI and Molecular Imaging Technologies

MRI remains the most sensitive imaging modality for high-risk populations due to superior contrast resolution (Greenwood, Dodelzon, & Katzen, 2018). Innovations such as contrast-enhanced MRI, diffusion-weighted imaging, and abbreviated MRI protocols improve efficiency and accessibility (Mincey & Perez, 2004). Molecular imaging techniques—including PEM, optical imaging, and molecular breast imaging (MBI)—offer functional and metabolic insights, enabling early detection before structural changes become visible (Díaz, Rodríguez-Ruiz, & Sechopoulos, 2024).

2.5 Integration of Artificial Intelligence in Breast Cancer Screening

AI and machine learning have transformed traditional screening workflows (Díaz, Rodríguez-Ruiz, & Sechopoulos, 2024). AI-enhanced algorithms can rapidly analyze imaging data, detect subtle abnormalities, reduce interpretive errors, and support personalized risk assessment strategies (Pulumati et al., 2023).

2.6 Emerging Non-Invasive and Biomarker-Based Techniques

Liquid biopsies, circulating tumor DNA, exosomes, and other biomarkers offer non-invasive methods for early detection and monitoring (Pulumati et al., 2023; Abdul Halim et al., 2021). These approaches provide opportunities for individualized screening and risk stratification before tumors are detectable via imaging.

2.7 Barriers, Ethical Considerations, and Future Directions

Challenges include high costs, limited access to advanced imaging, trained personnel shortages, and infrastructural constraints in low- and middle-income regions (Alshawwa et al., 2024; Lafi et al., 2024). Ethical concerns such as overdiagnosis, patient anxiety, and data privacy also require ongoing attention (Ayer, 2015). Future directions point toward integrated, AI-driven, cost-effective, and personalized screening models.

3. Methodology

This study adopted a qualitative systematic review approach to examine recent advances in breast cancer screening technologies. The review design was selected because it allows for a structured assessment and synthesis of existing scholarly evidence, enabling the identification of major technological developments and ongoing challenges in breast cancer diagnostics. The research relied entirely on secondary data from published literature and did not involve human participants or primary data collection.

To gather relevant information, an extensive search was conducted across reputable scientific databases, including PubMed, Scopus, ScienceDirect, Google Scholar, and the World Health Organization's digital library. The search strategy incorporated specific keywords and key phrases such as *breast cancer screening*, *digital breast tomosynthesis*, *advanced imaging*, *automated breast ultrasound*, *AI in breast cancer diagnostics*, *molecular imaging*, and *liquid biopsy*. Boolean operators ("AND," "OR," and "NOT") were applied to refine search results and capture a wide range of studies. The review focused on publications from 2010 to 2025 to ensure the inclusion of recent technological advancements and contemporary clinical evidence.

The selection of sources was guided by clearly defined inclusion and exclusion criteria. Studies were included if they focused on breast cancer screening technologies, were published in peer-reviewed journals or authoritative medical reports, presented empirical findings or clinical evaluations, and were written in English. Studies were excluded if they discussed unrelated aspects of breast cancer such as treatment or palliative care, lacked scientific rigor, or provided outdated or duplicative information. This screening process ensured that only relevant, high-quality literature contributed to the final analysis.

Data extraction and analysis were conducted manually through a thematic review of the selected studies. Each article was evaluated for its methodological rigor, clinical relevance, and contribution to the understanding of current innovations in breast cancer screening. The studies were grouped into thematic categories such as mammography advancements, ultrasound innovations, MRI and molecular imaging developments, AI integration, and biomarker-based techniques. This thematic approach facilitated the identification of recurrent patterns, key strengths, limitations, and emerging trends across different technologies. The findings were synthesized narratively to present a comprehensive interpretation of how modern screening methods are evolving and their implications for improving early cancer detection.

Since this research utilized publicly available secondary data, no ethical approval was required. However, academic integrity was upheld by acknowledging all sources and ensuring that the reviewed literature was cited appropriately.

4. Results and Discussion

The systematic review revealed substantial advancements in breast cancer screening technologies over the past decade, reflecting the integration of novel imaging methods, artificial intelligence, and biomarker-based diagnostics (Abdul Halim et al., 2021; Alshawwa et al., 2024; Lafi et al., 2024). Digital mammography continues to serve as the primary screening modality; however, the emergence of Digital Breast Tomosynthesis (DBT), or 3D mammography, has significantly improved diagnostic accuracy (Smith, Hall, & Marcello, 2004; Vaughan, 2019). DBT reduces the limitations of tissue overlap present in conventional mammography, leading to higher detection rates of invasive breast cancers and lower recall rates. Studies consistently demonstrate that DBT is particularly effective in women with dense breast tissue, a population traditionally underserved by standard 2D imaging (Gegios, Peterson, & Fowler, 2023; Mincey & Perez, 2004). These findings suggest that 3D mammography is becoming an essential component of modern screening programs.

In parallel, ultrasound-based technologies have also evolved. Automated Breast Ultrasound (ABUS) addresses the operator dependency and limited reproducibility of traditional handheld ultrasound (Alshawwa et al., 2024; Lafi et al., 2024). ABUS provides consistent, high-resolution imaging of the entire breast and has shown increased detection rates, particularly for small, node-negative tumors. Furthermore, advanced ultrasound techniques such as elastography improve tissue characterization, allowing clinicians to differentiate benign from malignant lesions more accurately (Irwig, Houssami, & Van Vliet, 2004). Collectively, these advancements position ultrasound as a valuable complementary modality to mammography, especially in populations with dense breast tissue or where mammographic sensitivity is reduced (Smith, Hall, & Marcello, 2004).

Magnetic Resonance Imaging (MRI) remains the most sensitive modality for high-risk women, offering superior contrast resolution and the ability to detect early-stage malignancies (Greenwood, Dodelzon, & Katzen, 2018; Mincey & Perez, 2004). Innovations such as contrast-enhanced MRI, diffusion-weighted imaging, and abbreviated MRI protocols have increased accessibility, reduced scanning time, and enhanced diagnostic confidence (Smith & Andreopoulou, 2004). Beyond MRI, molecular imaging techniques—including positron emission mammography (PEM) and molecular breast imaging (MBI)—provide functional and metabolic insights into tumor biology (Díaz, Rodríguez-Ruíz, & Sechopoulos, 2024; Vaughan, 2019). These modalities are particularly valuable for identifying tumors at the cellular level, which may not yet manifest as structural changes detectable by conventional imaging (Wright & McGechan, 2003).

The integration of Artificial Intelligence (AI) into breast cancer screening represents a transformative development. AI algorithms enhance the detection of subtle abnormalities, reduce diagnostic errors, and assist radiologists in interpreting large volumes of imaging data efficiently (Díaz, Rodríguez-Ruíz, & Sechopoulos, 2024; Pulumati et al., 2023). Additionally, AI models that incorporate patient demographics, genetic risk factors, and imaging findings allow for personalized risk assessment and targeted screening strategies. Several studies report that AI-assisted screening improves sensitivity and specificity, demonstrating the potential to optimize resource allocation and reduce unnecessary interventions (Abdul Halim et al., 2021; Ayer, 2015).

Emerging non-invasive biomarker-based approaches, such as liquid biopsies and circulating tumor DNA analysis, offer complementary diagnostic potential (Pulumati et al., 2023; Abdul Halim et al., 2021). These methods enable early detection of molecular changes associated with tumor development, providing opportunities for risk stratification and personalized monitoring. While still largely in experimental or pilot stages, these innovations suggest a future where screening may combine imaging with molecular diagnostics for more precise and individualized detection (Alshawwa et al., 2024; Lafi et al., 2024).

Despite these advances, challenges remain. High costs, limited access to advanced technologies, and the need for trained personnel restrict widespread implementation, particularly in low- and middle-income regions (Gegios, Peterson, & Fowler, 2023; Greenwood, Dodelzon, & Katzen, 2018). Ethical concerns, such as overdiagnosis, patient anxiety, and data privacy in AI-driven diagnostics, also require careful consideration (Ayer, 2015; Díaz, Rodríguez-Ruíz, & Sechopoulos, 2024). Nevertheless, the cumulative evidence demonstrates that technological innovations are improving early detection, enhancing diagnostic accuracy, and moving the field toward more personalized and effective breast cancer screening (Mincey & Perez, 2004; Smith & Andreopoulou, 2004).

5. Conclusion

Breast cancer screening has experienced remarkable advancements in recent years, reflecting the convergence of technological innovation, clinical research, and digital intelligence. Traditional methods, including mammography, ultrasound, and MRI, remain

fundamental to early detection; however, emerging technologies such as Digital Breast Tomosynthesis (3D mammography), Automated Breast Ultrasound (ABUS), and advanced MRI protocols have significantly enhanced diagnostic accuracy and sensitivity. These innovations are particularly effective for women with dense breast tissue or those at high genetic risk, populations that have historically faced limitations with conventional screening techniques.

The integration of Artificial Intelligence (AI) into imaging workflows represents a transformative development, offering the ability to detect subtle abnormalities, reduce interpretive errors, and facilitate risk-based, personalized screening strategies. AI-powered systems not only support radiologists in diagnostic decision-making but also optimize screening efficiency, potentially lowering healthcare costs associated with unnecessary interventions. In parallel, emerging non-invasive molecular diagnostics, including liquid biopsies and circulating tumor DNA analysis, show promise in detecting cancer at the cellular level before structural changes appear, paving the way for more individualized and preventive approaches to breast cancer management.

Despite these promising advancements, challenges remain in ensuring equitable access, particularly in low-resource settings where advanced imaging technologies and trained personnel are limited. Ethical considerations, such as overdiagnosis, patient anxiety, and data privacy in AI-driven diagnostics, also warrant careful attention. Addressing these barriers requires multidisciplinary collaboration, robust clinical validation, and policies that support affordable, accessible, and effective screening programs.

In conclusion, the evolution of breast cancer screening technologies is reshaping early detection and improving patient outcomes. By combining advanced imaging, AI integration, and molecular diagnostics, the field is moving toward more accurate, personalized, and preventive strategies. Continued research, innovation, and equitable implementation will be essential to fully realize the potential of these technologies, ultimately reducing breast cancer morbidity and mortality on a global scale.

References

- [1] Abdul Halim, A. A., Andrew, A. M., Mohd Yasin, M. N., Abd Rahman, M. A., Jusoh, M., Veeraperumal, V., ... Scavino, E. (2021). Existing and emerging breast cancer detection technologies and its challenges: A review. *Applied Sciences*, 11(22), 10753. <https://doi.org/10.3390/app112210753>
- [2] Alshawwa, I. A., El-Mashharawi, H. Q., Salman, F. M., Al-Qumboz, M. N. A., Abunasser, B. S., & Abu-Naser, S. S. (2024). Advancements in early detection of breast cancer: Innovations and future directions.
- [3] Ayer, T. (2015). Inverse optimization for assessing emerging technologies in breast cancer screening. *Annals of Operations Research*, 230(1), 57–85. <https://doi.org/10.1007/s10479-013-1424-7>
- [4] Díaz, O., Rodríguez-Ruiz, A., & Sechopoulos, I. (2024). Artificial intelligence for breast cancer detection: Technology, challenges, and prospects. *European Journal of Radiology*, 175, 111457. <https://doi.org/10.1016/j.ejrad.2023.111457>
- [5] Gegios, A. R., Peterson, M. S., & Fowler, A. M. (2023). Breast cancer screening and diagnosis: Recent advances in imaging and current limitations. *PET Clinics*, 18(4), 459–471. <https://doi.org/10.1016/j.cpet.2023.06.004>
- [6] Greenwood, H. I., Dodelzon, K., & Katzen, J. T. (2018). Impact of advancing technology on diagnosis and treatment of breast cancer. *Surgical Clinics*, 98(4), 703–724. <https://doi.org/10.1016/j.suc.2018.02.007>
- [7] Irwig, L., Houssami, N., & Van Vliet, C. (2004). New technologies in screening for breast cancer: A systematic review of their accuracy. *British Journal of Cancer*, 90(11), 2118–2122. <https://doi.org/10.1038/sj.bjc.6601834>
- [8] Lafi, O. I., Albanna, R. N., Alborn, D. F., Altarazi, R. E., Nabahin, A., Abu-Nasser, B. S., & Abu-Naser, S. S. (2024). Breakthroughs in breast cancer detection: Emerging technologies and future prospects.
- [9] Mincey, B. A., & Perez, E. A. (2004, June). Advances in screening, diagnosis, and treatment of breast cancer. In *Mayo Clinic Proceedings* (Vol. 79, No. 6, pp. 810–816). Elsevier. <https://doi.org/10.4065/79.6.810>
- [10] Pulumati, A., Pulumati, A., Dwarakanath, B. S., Verma, A., & Papineni, R. V. (2023). Technological advancements in cancer diagnostics: Improvements and limitations. *Cancer Reports*, 6(2), e1764. <https://doi.org/10.1002/cnr2.1764>
- [11] Smith, A. P., Hall, P. A., & Marcello, D. M. (2004). Emerging technologies in breast cancer detection. *Radiology Management*, 26(4), 16–27.
- [12] Smith, J. A., & Andreopoulou, E. (2004). An overview of the status of imaging screening technology for breast cancer. *Annals of Oncology*, 15, i18–i26. <https://doi.org/10.1093/annonc/mdh065>
- [13] Vaughan, C. L. (2019). Novel imaging approaches to screen for breast cancer: Recent advances and future prospects. *Medical Engineering & Physics*, 72, 27–37. <https://doi.org/10.1016/j.medengphy.2019.06.002>
- [14] Wright, T., & McGeachan, A. (2003). Breast cancer: New technologies for risk assessment and diagnosis. *Molecular Diagnosis*, 7(1), 49–55. [https://doi.org/10.1016/S1526-0577\(03\)00005-6](https://doi.org/10.1016/S1526-0577(03)00005-6)